Evidence map›Paper›PMID 42857293›Full record

ArticleExploration (Beijing, China)2026

Soluble Nanomedicine Against Soluble Neurosensitizers to Effectively Relieve Osteoarthritis Pain and Joint Damage.

Junyan Liu, Feixiang Ding, Jiayi Li, Min Liu, Lingyu Su, Zixi Wang, Congying Pi, Shilong Jiang, Zhaokui Zeng, Changjun Li and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Exploration (Beijing, China), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Junyan Liu *Department of Orthopaedics The Third Xiangya Hospital Central South University Changsha China.
Feixiang Ding *Xiangya School of Pharmaceutical Sciences Central South University Changsha China.
Jiayi LiDepartment of Pharmacology and Chemical Biology College of Basic Medical Sciences Shanghai Jiao Tong University School of Medicine Shanghai China.
Min LiuXiangya School of Pharmaceutical Sciences Central South University Changsha China.
Lingyu SuXiangya School of Pharmaceutical Sciences Central South University Changsha China.
Zixi WangXiangya School of Pharmaceutical Sciences Central South University Changsha China.
Congying PiXiangya School of Pharmaceutical Sciences Central South University Changsha China.
Shilong JiangDepartment of Pharmacy Xiangya Hospital Central South University Changsha China.
Zhaokui ZengXiangya School of Pharmaceutical Sciences Central South University Changsha China.
Changjun LiKey Laboratory of Aging-Related Bone and Joint Diseases Prevention and Treatment Ministry of Education Xiangya Hospital Central South University Changsha China.
Chao ZengDepartment of Orthopaedics Xiangya Hospital Central South University Changsha China.
Guanghua LeiDepartment of Orthopaedics Xiangya Hospital Central South University Changsha China.
Kelong AiXiangya School of Pharmaceutical Sciences Central South University Changsha China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Targeting soluble neurosensitizers in the osteoarthritis (OA) joint cavity is a key strategy for alleviating OA pain. Soluble neurosensitizers are ubiquitous in the joint cavity and cause uncontrollable growth and sensitization of nociceptor axons therein. However, eliminating these soluble nerve growth factors (NGFs) remains a considerable challenge due to the diversity of neurosensitizers and the complexity of OA pathology. This study introduces an innovative soluble nanodrug (LAC)-based strategy to eliminate three key neurosensitizers (H

Indexed as

joint painneurosensitizerosteoarthritissensory perceptionsynovial inflammation

Identifiers

PMID42857293
PMCPMC13650196

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.